A detailed history of Redmile Group, LLC transactions in Allakos Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 3,077,828 shares of ALLK stock, worth $4.34 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
3,077,828
Previous 3,451,076 10.82%
Holding current value
$4.34 Million
Previous $4.35 Million 29.23%
% of portfolio
0.2%
Previous 0.17%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.0 - $1.45 $373,248 - $541,209
-373,248 Reduced 10.82%
3,077,828 $3.08 Million
Q1 2024

May 15, 2024

SELL
$1.02 - $3.23 $223,758 - $708,568
-219,371 Reduced 5.98%
3,451,076 $4.35 Million
Q4 2023

Feb 14, 2024

BUY
$1.72 - $3.18 $2.39 Million - $4.41 Million
1,386,853 Added 60.73%
3,670,447 $10 Million
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $9,298 - $13,560
-2,583 Reduced 0.11%
2,283,594 $9.96 Million
Q1 2023

May 15, 2023

SELL
$4.3 - $8.27 $1.11 Million - $2.14 Million
-259,098 Reduced 10.18%
2,286,177 $10.2 Million
Q2 2022

Aug 15, 2022

SELL
$2.6 - $6.14 $38,220 - $90,258
-14,700 Reduced 0.57%
2,545,275 $7.97 Million
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $2.45 Million - $4.73 Million
482,100 Added 23.2%
2,559,975 $14.6 Million
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $461,024 - $6.03 Million
-53,921 Reduced 2.53%
2,077,875 $20.3 Million
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $6.52 Million - $9.41 Million
-85,200 Reduced 3.84%
2,131,796 $226 Million
Q2 2021

Aug 16, 2021

SELL
$85.37 - $114.1 $17.3 Million - $23.1 Million
-202,422 Reduced 8.37%
2,216,996 $189 Million
Q1 2021

May 17, 2021

SELL
$109.73 - $153.66 $27.2 Million - $38.1 Million
-248,033 Reduced 9.3%
2,419,418 $278 Million
Q4 2020

Feb 16, 2021

BUY
$79.58 - $152.45 $19.2 Million - $36.9 Million
241,891 Added 9.97%
2,667,451 $373 Million
Q3 2020

Nov 16, 2020

SELL
$66.43 - $90.99 $12.9 Million - $17.6 Million
-193,520 Reduced 7.39%
2,425,560 $198 Million
Q2 2020

Aug 14, 2020

SELL
$44.04 - $80.69 $15.8 Million - $28.9 Million
-357,848 Reduced 12.02%
2,619,080 $188 Million
Q1 2020

May 15, 2020

SELL
$44.49 - $93.39 $2.52 Million - $5.29 Million
-56,598 Reduced 1.87%
2,976,928 $132 Million
Q4 2019

Feb 14, 2020

SELL
$66.49 - $137.73 $2.9 Million - $6.01 Million
-43,602 Reduced 1.42%
3,033,526 $289 Million
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $24.1 Million - $69.7 Million
776,827 Added 33.77%
3,077,128 $242 Million
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $16.8 Million - $20.8 Million
465,891 Added 25.4%
2,300,301 $99.7 Million
Q1 2019

May 15, 2019

BUY
$33.79 - $51.99 $4.59 Million - $7.06 Million
135,762 Added 7.99%
1,834,410 $74.3 Million
Q4 2018

Feb 14, 2019

BUY
$31.59 - $62.65 $7.54 Million - $15 Million
238,756 Added 16.35%
1,698,648 $88.8 Million
Q3 2018

Nov 14, 2018

BUY
$31.25 - $47.64 $45.6 Million - $69.5 Million
1,459,892 New
1,459,892 $65.7 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $119M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.